With the development of organ transplantation, many immunosuppressive agents such as cyclosporine, tacrolimus and mycophenolate mofetil can significantly reduce the incidence of acute rejection, and the long-term survival rate of transplants has also been significantly improved. However, the development of immunosuppressive agents with high efficiency and low toxicity is still one of the focuses of drug research. Sirolomus, as a new immunosuppressant, has the characteristics of high efficiency and low toxicity. Sirolimus dispersible tablets are easy to take and absorb, with less gastrointestinal irritation, especially suitable for the elderly and those with dysphagia, and the loss of drugs in the whole absorption process is small. Owing to the addition of hydroxypropyl beta-cyclodextrin, which has good disintegration performance, it has the characteristics of good stability, rapid disintegration and dissolution in water, forming uniform suspension and high bioavailability. The preparation process is simple and has no special requirements for equipment, so it is suitable for large-scale production.